Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Next Previous
X
Search
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Etrumadenant (Primary) ; Hyaluronidase (Primary) ; Motixafortide (Primary) ; Selicrelumab (Primary) ; Simlukafusp alfa (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Morpheus-Pancreatic Cancer; MORPHEUS-PDAC
  • Sponsors Roche

    • Most Recent Events

    • 08 Nov 2024 Planned End Date changed from 31 Oct 2026 to 31 Jan 2025.
    • 08 Nov 2024 Planned primary completion date changed from 31 Oct 2025 to 31 Jan 2025.
    • 05 Jun 2024 According to results presented at the 115th Annual Meeting of the American Association for Cancer Research, the ORR primary endpoint was not met although both median PFS and OS were numerically improved with the combination therapy of atezolizumab + etrumadenant + chemotherapy suggesting that the addition of etruma and atezo may confer a benefit.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top